Table 1.

Results from Published Trials Involving Bimekizumab in Psoriatic Arthritis

	Registration	ACR20	ACR50	PASI75	PASI100	PGA	PtGA
Phase I PA00077	NCT02141763	Bimekizumab arm (at week 8)
		80%	40%	100%	87%	−64%	− 59%
		Placebo arm
		16.7%	8.3%	0%	0%	−29%	−17%
Phase II BE ACTIVE8	NCT02969525	Bimekizumab arm (at week 12)
		59.75%*	34.5%**	64.75%***	35.25%****
		Placebo arm
		19%	7%	7%	7%

Notes: P(hysician) GA and Pt(atient) GA – % change from baseline. *Average for all bimekizumab treatment groups, max 73% (160 mg), min 51% 320 mg. **Average for all bimekizumab treatment groups, max 46% (160 mg loading dose), min 24% 320 mg. ***Average for all bimekizumab treatment groups, max 77% (160 mg loading dose), min 45% 16 mg. ****Average for all bimekizumab treatment groups, max 54% (160 mg loading dose), min 21% 16 mg.